Tesofensine vs Omentin-1
Head-to-head comparison of Tesofensine (Tesofensine (NS2330)) and Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Tesofensine | Omentin-1 |
|---|---|---|
| Category | Weight Management | Diabetes & Metabolic |
| Full Name | Tesofensine (NS2330) | Omentin-1 (Intelectin-1, ITLN1) |
| Molecular Weight | 426.52 g/mol | ~35 kDa |
| Half-Life | ~200-300 hours | hours |
| Amino Acids | Small molecule | 313 |
| Typical Dose | — | No approved human dose; research use only |
| Route | — | IV|SC |
| Purity | >98% | ≥98% |
| Studies Count | 35 | 82 |
| Research Status | Phase III Clinical Trials | Pre-clinical |
Tesofensine Benefits
- ✓Potent appetite suppression, increased metabolic rate, enhanced thermogenesis, improved mood during dieting, reduces food reward-seeking behavior
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Tesofensine Dosing
Clinical doses: 0.25-1.0 mg orally once daily. Research typically uses 0.5 mg. Extremely long half-life (8-13 days) means steady-state in 7-10 days.
Omentin-1 Dosing
not established|not established
Tesofensine Side Effects
- ⚠Dry mouth, insomnia, constipation, increased heart rate, elevated blood pressure. Not recommended with uncontrolled hypertension.
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Research Overview
Tesofensine
Phase II trials showed 12.8 kg average weight loss at 1.0 mg dose over 6 months. Simultaneously inhibits reuptake of norepinephrine, dopamine, and serotonin, producing appetite suppression and increased thermogenesis.
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.